Telomir Pharmaceuticals, INC 8-K filings

Telomir Pharmaceuticals, Inc. completed a block sale of 1.1 million common shares to institutional investors at a premium, generating approximately $2.9 million in gross proceeds.

Telomir Pharmaceuticals announced new preclinical data showing its lead candidate, Telomir-1, fully reversed STAT1 gene silencing in human prostate cancer cells, demonstrating stronger epigenetic effects than Paclitaxel or Rapamycin.

Telomir Pharmaceuticals, Inc. announced positive new preclinical data demonstrating the cellular protective activity of its lead candidate, Telomir-1, in human progeria cell lines, indicating potential for a novel treatment for the ultra-rare pediatric aging disorder.

Telomir Pharmaceuticals, Inc. announced new preclinical data demonstrating its lead small molecule candidate, Telomir-1, significantly improved neurological, behavioral, liver, and kidney outcomes in an animal model of Wilsons disease.

Telomir Pharmaceuticals announced highly positive preclinical results for its lead compound, Telomir-1, demonstrating its ability to reset biological aging markers, extend telomere length, and achieve 100% survival in an animal model of Werner Syndrome.

Telomir Pharmaceuticals, Inc. announced substantial preclinical advancements for its lead candidate Telomir-1 and a new drug Telomir-Ag2, alongside plans for an IND submission by year-end and participation in the BIO International Convention for strategic collaborations.

Telomir Pharmaceuticals, Inc. announced significant preclinical data for its investigational oral small molecule Telomir-1, showing restoration of vision and retinal structure in an age-related macular degeneration (AMD) animal model.

Telomir Pharmaceuticals announces the appointment of Alan Weichselbaum as Chief Financial Officer, effective May 15, 2025, following the mutual separation of Michelle Yanez from the same role.

Telomir Pharmaceuticals raised $3 million through a direct equity investment from its largest shareholder to support regulatory and development activities, including an upcoming IND submission for a rare disease indication.

Telomir Pharmaceuticals announces the identification of Telomir-Ag2, a novel drug candidate with broad-spectrum antibacterial activity, following successful preclinical validation.

Telomir Pharmaceuticals reports that its drug candidate, Telomir-1, shows promise in reversing key drivers of cellular decline in human cell lines, potentially benefiting conditions like autism and spasmodic dysphonia.

Telomir Pharmaceuticals reports that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model, suppresses cancer progression, and neutralizes chemotherapy toxicity.

Telomir Pharmaceuticals reports that Telomir-1 reverses calcium dysregulation, a key driver of aging and disease, in multiple human cell lines, according to new preclinical findings.

Telomir Pharmaceuticals announces a breakthrough in stabilizing Silver(I) and Silver(II) ions, potentially unlocking a multi-billion-dollar medical market.

Telomir Pharmaceuticals reports that its lead compound, Telomir-1, significantly reduced oxidative stress in human retinal cell lines, suggesting potential for treating age-related macular degeneration (AMD).

Telomir Pharmaceuticals reports that its drug, Telomir-1, has demonstrated the ability to fully reverse oxidative stress in human cell lines, showing potential for treating diseases linked to oxidative damage and viral infections.

Telomir Pharmaceuticals reports successful preclinical trial results showing their drug, Telomir-1, restored lifespan in nematodes with a progeria-like condition.

Telomir Pharmaceuticals reports preclinical studies showing Telomir-1's strong copper-binding capabilities, positioning it as a potential treatment for Wilson's disease and other copper-related conditions.

Telomir Pharmaceuticals has announced the resignation of its independent auditor, Cherry Bekaert LLP, and the engagement of Salberg & Company P.A. as its new auditor.

Telomir Pharmaceuticals raised $1 million by issuing common stock at a 20% premium to the closing price, without any warrants.

Telomir Pharmaceuticals reports successful preclinical trial results showing its drug, Telomir-1, reversed insulin resistance in a zebrafish model of Type 2 diabetes.

Telomir Pharmaceuticals reports the resignation of Michael Jerman from the Board and Audit Committee, and the appointment of Dr. Matthew Del Giudice and Matthew Pratt Whalen to the Audit Committee.

Telomir Pharmaceuticals reports significant age-reversal effects in preclinical studies using Telomir-1, showing increased lifespan, improved mobility, and a reversal of age-related decline.

Telomir Pharmaceuticals has entered into a $5 million unsecured loan agreement with The Starwood Trust, a related-party trust, to enhance financial flexibility and support operations.

Telomir Pharmaceuticals has appointed Dr. Itzchak Angel, a former head of pharmacology at Synthelabo (now Sanofi-Aventis), as Chief Scientific Advisor to lead the company's IND and INAD applications.

Telomir Pharmaceuticals has appointed Michelle Yanez as its new Chief Financial Officer, effective June 18, 2024, following the resignation of Nathan Fuentes.

Telomir Pharmaceuticals presented its recent preclinical data and preclinical and clinical study plans at the National Press Club on April 15, 2024.

Telomir Pharmaceuticals announces the immediate resignation of its General Counsel and Board member, Christos Nicholoudis, effective April 10, 2024.

Telomir Pharmaceuticals successfully closed its initial public offering, raising $7 million before expenses, and began trading on the Nasdaq Capital Market under the ticker symbol TELO.